Erlotinib intermediates manufacturer

2-Amino-4,5-bis(2-methoxyethoxy)benzonitrile
Tel: +86-311-67260775 sales@dingminpharma.com
Products
Your location: Home » Products > API

Anti-cancer PF299804 Dacomitinib cas 1110813-31-4

Dacomitinib is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types.
Send your message to us
(* We will reply your inquiry to this Email as soon as we see it.)
Product:
Name: *
E-mail: *
Tel:
Message: *
Verification Code: *图片看不清?点击重新得到验证码
Other Products
PRODUCTS LIST
CONTACT US
Office Address: No.41, Zhaiying South Street, Yuhua District, Shijiazhuang, Hebei Province.Chinaa
R&D and Plant Address: Jinzhou Industry Park, Jinzhou County, Shijizhuang, Hebei Province.China
Tel: +86-311-67260775
Fax: +86-311-67591193
sales@dingminpharma.com
Online Service×